A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and/...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques Da Costa, Maria Eugénia, Zaidi, Sakina, Scoazec, Jean-Yves, Droit, Robin, Lim, Wan Ching, Marchais, Antonin, Salmon, Jerome, Cherkaoui, Sarah, Morscher, Raphael J., Laurent, Anouchka, Malinge, Sébastien, Mercher, Thomas, Tabone-Eglinger, Séverine, Goddard, Isabelle, Pflumio, Francoise, Calvo, Julien, Redini, Francoise, Entz-Werlé, Natacha, Soriano, Aroa, Villanueva, Alberto, Cairo, Stefano, Chastagner, Pascal, Moro, Massimo, Owens, Cormac, Casanova, Michela, Hladun-Alvaro, Raquel, Berlanga, Pablo, Daudigeos-Dubus, Estelle, Dessen, Philippe, Zitvogel, Laurence, Lacroix, Ludovic, Pierron, Gaelle, Delattre, Olivier, Schleiermacher, Gudrun, Surdez, Didier, Geoerger, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507044/
https://www.ncbi.nlm.nih.gov/pubmed/37723198
http://dx.doi.org/10.1038/s42003-023-05320-0

Ejemplares similares

Ejemplares similares